These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22220931)

  • 1. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention.
    Meng S; Wang LS; Huang ZQ; Zhou Q; Sun YG; Cao JT; Li YG; Wang CQ
    Clin Exp Pharmacol Physiol; 2012 May; 39(5):406-11. PubMed ID: 22220931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1.
    Nomoto K; Oguchi S; Watanabe I; Kushiro T; Kanmatsuse K
    J Cardiol; 2003 Nov; 42(5):201-6. PubMed ID: 14658408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes.
    Postadzhiyan AS; Tzontcheva AV; Kehayov I; Finkov B
    Clin Biochem; 2008 Feb; 41(3):126-33. PubMed ID: 18061588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
    Patti G; Chello M; Gatto L; Alfano G; Miglionico M; Covino E; Di Sciascio G
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):795-800. PubMed ID: 20613550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value.
    Lewandowski M; Kornacewicz-Jach Z; Millo B; Zielonka J; Czechowska M; Kaliszczak R; Płońska E; Goracy J; Kaźmierczak J; Naruszewicz M
    Cardiol J; 2008; 15(4):357-64. PubMed ID: 18698545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome.
    Jia XW; Fu XH; Zhang J; Gu XS; Fan WZ; Wu WL; Hao GZ; Li SQ; Jiang YF
    Chin Med J (Engl); 2009 Mar; 122(6):659-64. PubMed ID: 19323930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum adhesion molecule levels in acute coronary syndrome among Indonesian patients.
    Alwi I
    Acta Med Indones; 2008 Jul; 40(3):135-8. PubMed ID: 18845851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention.
    Xu HY; Qiao SB; Zhang JF; Dong QT; Li JJ
    Coron Artery Dis; 2012 May; 23(3):181-7. PubMed ID: 22336660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Oh SK; Rhee SJ; Yoo NJ; Kim NH; Jeong JW
    Int J Cardiol; 2011 Jan; 146(1):68-72. PubMed ID: 20471117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of plasma brain natriuretic peptide and C-reactive protein in patients with acute coronary syndromes underwent percutaneous coronary intervention].
    He B; Ding S; Pu J; Liu JP; Song W; Du YP; Shen JY; Jin SX; Sun Y; Shen L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Apr; 34(4):349-52. PubMed ID: 16776932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of statin therapy on coronary intervention for non-ST elevation acute coronary syndrome with decreased low-density lipoprotein cholesterol.
    Hara H; Nakamura M; Yokouchi I; Kimura K; Nemoto N; Ito S; Ono T; Shiba M; Wada M; Tsuji T; Komatsu H; Iijima R; Nakajima R; Yamamoto M; Yamamoto M; Yoshitama T; Takagi T; Hara H; Sugi K
    J Cardiol; 2007 Mar; 49(3):115-23. PubMed ID: 17444137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.
    Wang JN; Yan YY; Guo ZY; Jiang YJ; Liu LL; Liu B
    Chin Med J (Engl); 2016 Dec; 129(23):2786-2791. PubMed ID: 27900989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
    Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM
    Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome.
    Shu J; Ren N; Du JB; Zhang M; Cong HL; Huang TG
    Scand Cardiovasc J; 2007 Jun; 41(3):149-54. PubMed ID: 17487763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy comparison with low and high dose nadroparin for patients with acute coronary syndrome underwent percutaneous coronary intervention].
    Sun CY; Xia HY; Li XQ; Jin LJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jun; 36(6):493-6. PubMed ID: 19100058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent.
    Wu Y; Zhang W; Liu W; Zhuo X; Zhao Z; Yuan Z
    Atherosclerosis; 2011 Mar; 215(1):170-5. PubMed ID: 21227422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention.
    Robertson L; Grip L; Mattsson Hultén L; Hulthe J; Wiklund O
    J Intern Med; 2007 Dec; 262(6):659-67. PubMed ID: 17927738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.